Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 449,295 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at 14.24 on Thursday. The company has a 50-day moving average price of $14.44 and a 200-day moving average price of $11.03. The stock’s market capitalization is $2.34 billion. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The business had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “John F. Crowley Sells 449,295 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/19/john-f-crowley-sells-449295-shares-of-amicus-therapeutics-inc-fold-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its holdings in Amicus Therapeutics by 3,672.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after purchasing an additional 66,209 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Amicus Therapeutics by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock valued at $5,541,000 after purchasing an additional 41,711 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at $1,057,000. Geode Capital Management LLC increased its holdings in Amicus Therapeutics by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock valued at $8,323,000 after purchasing an additional 52,003 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares in the last quarter.

FOLD has been the subject of several research analyst reports. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Robert W. Baird restated an “outperform” rating and set a $12.00 price target on shares of Amicus Therapeutics in a research report on Friday, June 30th. Cowen and Company restated a “buy” rating and set a $16.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.81.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.